Buy Phenibut 250mg 100 tablets

Inside, after eating.

Adults appoint 250-500 mg 3 times a day.

The maximum single dose in adult patients is 750 mg, in patients older than 60 years, 500 mg.

The course of treatment is 2-3 weeks. If necessary, the course can be extended to 4-6 weeks. The duration of the course of treatment is determined by the doctor, taking into account the characteristics of the disease, the tolerability of the drug and the effect achieved.

Children aged 8 to 14 years - 250 mg 3 times a day. Children over 14 years of age are prescribed doses for adults.

For relief of alcohol withdrawal syndrome in the first days of treatment - 250-500 mg 3 times a day and 750 mg - at night, with a gradual decrease in the daily dose to the usual for adults.

In case of illness and Meniere's syndrome during an exacerbation - 750 mg 3 times a day for 5-7 days, with a decrease in the severity of vestibular disorders - 250-500 mg 3 times a day for 5-7 days and then 250 mg 1 time per day for 5 days. For mild disease, 250 mg twice a day for 5-7 days, followed by a dose reduction of 250 mg once a day for 7-10 days.

For treatment of dizziness with dysfunctions of the vestibular analyzer of vascular and traumatic genesis - 250 mg 3 times a day for 12 days.

For the prevention of motion sickness - 250-500 mg once for 1 hour before the proposed journey (the effect is dose-dependent nature). Phenibut is ineffective in the development of pronounced motion sickness ("indomitable" vomiting, dizziness and other symptoms).

Patients with impaired liver function could have a hepatotoxic effect with high doses of phenibut. Patients in this group are given smaller doses of the drug under the control of liver function.

There is no evidence of adverse effects of phenibut on patients with impaired renal function when taking therapeutic doses.

Classification of undesirable adverse reactions according to the frequency of development: very often (≥1 / 10); often (≥ 1/100 to <1/10); infrequently (≥ 1/1000 to <1/100); rarely (≥ 1/10 000 to <1/1000); very rarely (<1/10 000).

Disturbances from the nervous system *: drowsiness (at the beginning of treatment), increased irritability, agitation, anxiety, dizziness, headache.

Disorders from the gastrointestinal tract *: nausea (at the beginning of treatment).

Disturbances from the skin and subcutaneous tissues: rarely - allergic reactions (skin rash, itching).

Disorders from the liver and bile ducts *: with prolonged use of high doses - hepatotoxicity.

* - frequency of manifestation is not known (can not be determined from available data) .

With prolonged use, it is necessary to monitor the liver function and the peripheral blood picture.

Care should be taken in patients with erosive and ulcerative diseases of the gastrointestinal tract due to the irritant effect of the drug. These patients are prescribed smaller doses of the drug.

The preparation contains lactose. Do not use in patients with a rare congenital intolerance to galactose, a deficiency in Lapp's lactase, or glucose-galactose malabsorption.

Use in children. The drug in this form of release can be prescribed to children from 8 years of age.

Use during pregnancy and lactation. Adequate and well-controlled studies to assess the safety of drug use in women during pregnancy and lactation have not been carried out. Phenibut should not be used during pregnancy and lactation.

Influence on the ability to drive vehicles and other potentially dangerous mechanisms. It is necessary to refrain from potentially dangerous activities requiring increased attention.

Interaction with other drugs

Extends and intensifies the effect of hypnotics, narcotic analgesics, antiepileptic, antipsychotic and antiparkinsonian drugs.

Do not combine with alcohol.